Sam Ghilardi 4/14/26 Sam Ghilardi 4/14/26

C4's Partnership with Roche, Gilead Options Kymera degrader, and Astellas Licenses Dyno Capsid

Plus the initial dosing of Enanta and Avencell's Clinical Trials

Sam Ghilardi 3/17/26 Sam Ghilardi 3/17/26

Parallel Bio's Expansion into Therapeutics, and We're Looking Out for More Potential Cash Flow Challenges -Watertown Bio News RoundUp

Plus, where key opinion leaders see Watertown's biotech sector heading.

Sam Ghilardi 1/20/26 Sam Ghilardi 1/20/26

2025 Funding numbers are in, 2026 early raises, Lyra Therapeutics runs out of time and more

Sam Ghilardi 1/6/26 Sam Ghilardi 1/6/26

Neumora's positive clinical data , new tenants at the Arsenal, and more

Sam Ghilardi 11/18/25 Sam Ghilardi 11/18/25

Neumora's Wegovy alternative, Dyno announces manufacturing pact, and more

Sam Ghilardi 11/4/25 Sam Ghilardi 11/4/25

Soufflé Therapeutics Launches from Stealth, Disc and Werewolf receive FDA priority, Affini-T may be winding down.